 Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 | | 1997 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 4 | 4 | | 2005 | 3 | 3 | 6 | | 2006 | 6 | 7 | 13 | | 2007 | 10 | 4 | 14 | | 2008 | 6 | 11 | 17 | | 2009 | 6 | 6 | 12 | | 2010 | 22 | 11 | 33 | | 2011 | 10 | 10 | 20 | | 2012 | 17 | 13 | 30 | | 2013 | 26 | 12 | 38 | | 2014 | 24 | 14 | 38 | | 2015 | 24 | 13 | 37 | | 2016 | 19 | 18 | 37 | | 2017 | 17 | 11 | 28 | | 2018 | 32 | 19 | 51 | | 2019 | 29 | 21 | 50 | | 2020 | 13 | 10 | 23 | | 2021 | 12 | 14 | 26 | | 2022 | 7 | 28 | 35 | | 2023 | 1 | 25 | 26 | | 2024 | 7 | 18 | 25 | | 2025 | 22 | 6 | 28 | | 2026 | 7 | 0 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Drilon A, Cho BC, Camidge DR, Nagasaka M, Besse B, Solomon B, Goto K, Wolf J, Popat S, Felip E, Yang N, de Langen AJ, Lu S, Velcheti V, Lin AL, Calvet CY, Li L, Tschaika M, Afsar S, Yang H, Lin JJ. Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis. Oncologist. 2026 May 08; 31(6).
-
Piarowski CM, Scott JK, Wilson CE, Lara HI, Salcedo E, Han AS, Lam ET, Dempsey PJ, von Moltke J, Barlow LA. Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition. Development. 2026 Apr 15; 153(8).
-
Hinz TK, Le AT, Doan T, Ast A, Jaramillo S, Avila JT, Skhisov D, Haines S, Navarro AC, Patil T, Nemenoff RA, Heasley LE. Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma. Cancer Lett. 2026 Jun 28; 648:218467.
-
Besse B, Subbiah V, Curigliano G, Bowles DW, Doebele RC, Mansfield AS, Baik CS, de Lima Lopes G, Paz-Ares L, Taylor MH, Tan DSW, Alonso G, Gadgeel SM, Kalemkerian GP, Ou SI, van der Wekken AJ, Becerra CR, Evangelist M, Griesinger F, Liu SV, Lou Y, Mazières J, Melear JM, Narang M, Saxena A, Thomas M, Wang S, Thomassen A, Lee DH, Kim DW, Gainor JF. Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. J Clin Oncol. 2026 May; 44(13):1190-1197.
-
Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ. Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. Clin Cancer Res. 2026 Mar 16; 32(6):1157-1168.
-
Shah NJ, Sura S, Shinde R, Dai W, Wentworth C, Conkling P, Bupathi M, Vickery D, Perini R, Motzer RJ. Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study. Urol Oncol. 2026 Apr; 44(4):110979.
-
O'Connor TN, Schultz E, Kabraji S, Levine E, Williams AJ, Knudsen ES, Witkiewicz AK. Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors. JCO Precis Oncol. 2026 Jan; 10:e2500346.
-
Tomita Y, Link G, Ge Y, Gold ERH, Racanelli A, Cardona HJ, Romero M, Gadd S, Watanabe J, Uchida E, Hashizume R, Takata N, Pinero G, Hambardzumyan D, Spasojevic I, Hu G, Hennika T, Brat DJ, Green AL, Becher OJ. Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models. PLoS One. 2025; 20(12):e0323235.
-
Sine CC, Watts LP, Fernandez B, Marikar N, Wang J, Knudsen ES, Witkiewicz AK, Spencer SL. p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. Sci Signal. 2025 Nov 25; 18(914):eadv0415.
-
Waliany S, Roy SG, Pecci F, Weber UM, Sun F, Arter Z, Lomibao M, Alessi JV, Nishino M, Luo F, Repetto M, Falcon C, Do A, Peterson J, Liang J, Liu A, Nagasaka M, Ricciuti B, Drilon A, Ou SI, Neal JW, Patil T, Awad M, Yeap BY, Digumarthy SR, Lin JJ. Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study. J Natl Compr Canc Netw. 2025 Nov 19; 23(12):522-530.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|